Navigation Links
New treatment targeting versatile protein may protect brain cells in Parkinson's disease
Date:5/16/2014

In Parkinson's disease (PD), dopamine-producing nerve cells that control our movements waste away. Current treatments for PD therefore aim at restoring dopamine contents in the brain. In a new study from Lund University, researchers are attacking the problem from a different angle, through early activation of a protein that improves the brain's capacity to cope with a host of harmful processes. Stimulating the protein, called Sigma-1 receptor, sets off a battery of defence mechanisms and restores lost motor function. The results were obtained in mice, but clinical trials in patients may not be far away.

By activating the Sigma-1 receptor, a versatile protein involved in many cellular functions, levels of several molecules that help nerve cells build new connections increased, inflammation decreased, while dopamine levels also rose. The results, published in the journal Brain, show a marked improvement of motor symptoms in mice with a Parkinson-like condition that had been treated with a Sigma-1-stimulating drug for 5 weeks.

This treatment has never before been studied in connection with Parkinson's disease. However, various publications linked to stroke and motor neurone disease have reported positive results with drugs that stimulate the Sigma-1 receptor, and a biotech company in the US will soon begin clinical trials on Alzheimer's patients. The fact that substances stimulating this protein are already available for clinical use is a major advantage, according to Professor M. Angela Cenci Nilsson, head of the research team at Lund University.

"It is a huge advantage that these substances have already been tested in people and approved for clinical application. It means that we already know that the body tolerates this treatment. Clinical trials for Parkinson's disease could theoretically start any time". Boosting the brain's in-built defence mechanisms with approaches like this is a rather new idea in Parkinson's research. Professor Cenci Nilsson, however, believes that the number of targets for future treatments is increasing as we learn more and more about the complex effects of PD on many different types of cells in the brain.

"The motor improvements we have seen in mice are disproportionately large compared to the recovery of dopamine levels. We believe this is because the treatment has protected the brain against a series of indirect consequences triggered by the Parkinson-like lesion. For example, we know today that a loss of dopamine causes the target neurons to lose synapses, and also alters both neural pathways and non-neuronal cells in the brain. Since the Sigma-1 receptor is widely expressed in many cell types, the treatment could intervene in many of these damaging processes ".

The treatment was shown to be significantly more effective when started at the beginning of the most aggressive phase of dopamine cell death. As a future potential therapy for Parkinson's disease, this treatment would therefore need to be started as soon as possible after diagnosis in order to deliver maximum impact.

"In order to accelerate a possible clinical translation of our findings, we will now seek further evidence in support of this type of treatment. We are now discussing various opportunities with different collaborating partners, and we will try to procure funding for clinical studies in Parkinsons disease as soon as possible", concludes M. Angela Cenci Nilsson.


'/>"/>

Contact: M. Angela Cenci Nilsson
Angela.Cenci_Nilsson@med.lu.se
46-462-221-431
Lund University
Source:Eurekalert

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. Clinical insight improves treatment with new lung cancer drug
3. Rapid Asthma Treatment in ER May Prevent Admission
4. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
5. Breast cancer patients suffer treatment-related side effects long after completing care
6. Mayo Clinic offers newly approved treatment for acid reflux disease
7. Mobile Stroke Units Might Trim Time to Treatment
8. Breast Cancer Treatment Side Effects May Last for Years
9. Mouse Study Hints at New Path for Diabetes Treatment
10. Symptomatic behaviour in childhood strongly predicts psychiatric treatment as a young adult
11. Exercise improves quality of life during breast cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... A prescription medication bottle, ... the fourth Cradle to Cradle Product Design Challenge , the Cradle to ... series of six circular design challenges scheduled to run through early 2018. The challenges ...
(Date:1/17/2017)... ... January 17, 2017 , ... SC&H Group, a leading audit, tax, and ... its IT Advisory Services practice . Rossi is the third technology consulting leader ... strategic IT guidance grows, and the practice continues to expand.     , Bringing more than ...
(Date:1/17/2017)... ... January 17, 2017 , ... The Sharie Withers ... has announced the latest beneficiary of their thriving community involvement program. The current ... to fulfilling the dreams of terminally ill patients. Donations to this worthy cause ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... Center and the Montclair State University’s Athletic Training Education program forged a relationship ... Athletic Training Education Program, which is consists of both student members and ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... Gym Source, ... of a new showroom in East Hanover, New Jersey. , “We are elated to ... “The new innovative in-store concept is designed to give clients a seamless and motivating ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... the company that brought a full line of equine first aid ... line of companion animal pet first aid kits.  EquiMedic ... has developed two sizes of small pet first aid kits under ... Featuring a small and a large companion pet first aid kit, ... a newcomer to working with small animals either. Corporate owners, mother ...
(Date:1/17/2017)... , Jan. 17, 2016  Attorney Advertising -- Bronstein, ... of purchasers of Anthera Pharmaceuticals, Inc. ("Anthera" or the "Company") ... obtain additional information and assist the investigation by visiting the ... whether Anthera and certain of its officers and/or directors have ... of 1934. ...
(Date:1/17/2017)... 2017 Research and Markets has announced the ... Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug ... 2021" report to their offering. ... The global active pharmaceutical ingredients market is ... Billion in 2016, growing at a CAGR of 6.3% from 2016 ...
Breaking Medicine Technology: